$FLGT
Fulgent Genetics, Inc. Stock $flgt

$flgt Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024022233 Filed on February 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$64.49M	$70.51M	$289.2M
YoY Change	-2.54%	4.14%	-53.27%
Cost Of Revenue	$42.38M	$45.28M	$184.8M
YoY Change	-10.51%	-17.25%	-26.7%
Gross Profit	$22.10M	$25.23M	$104.5M
YoY Change	17.51%	94.26%	-71.53%
Gross Profit Margin	34.28%	35.78%	36.12%
Selling, General & Admin	$30.48M	$42.21M	$130.5M
YoY Change	-4.41%	8.09%	-13.02%
% of Gross Profit	137.88%	167.29%	124.9%
Research & Development	$11.43M	$11.95M	$41.44M
YoY Change	16.89%	40.46%	43.34%
% of Gross Profit	51.73%	47.37%	39.67%
Depreciation & Amortization	$6.663M	$6.533M	$26.14M
YoY Change	-3.14%	-33.35%	-19.96%
% of Gross Profit	30.14%	25.89%	25.03%
Operating Expenses	$43.90M	$56.12M	$300.0M
YoY Change	0.61%	13.28%	59.25%
Operating Profit	-$21.80M	-$30.89M	-$195.5M
YoY Change	-12.19%	-15.5%	-209.52%
Interest Expense	$7.625M	$5.925M	$21.44M
YoY Change	3712.5%	91.75%	6097.69%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$14.17M	-$145.2M	-$174.1M
YoY Change	-32.67%	333.91%	-194.6%
Income Tax	-$327.0K	-$10.86M	$1.154M
% Of Pretax Income
Net Earnings	-$13.46M	-$128.1M	-$167.8M
YoY Change	-12.24%	437.72%	-217.03%
Net Earnings / Revenue	-20.88%	-181.76%	-58.03%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.45	-$4.31	-$5.64
COMMON SHARES
Basic Shares Outstanding	29.78M	29.63M	29.78M
Diluted Shares Outstanding	29.77M		29.78M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$305.7M	$424.2M	$424.2M
YoY Change	-39.4%	-19.4%	-19.4%
Cash & Equivalents	$54.68M	$97.47M	$97.47M
Short-Term Investments	$251.0M	$326.7M	$326.7M
Other Short-Term Assets	$28.75M	$32.56M	$26.25M
YoY Change	-12.04%	-33.4%	136.58%
Inventory
Prepaid Expenses	$7.359M	$7.744M
Receivables	$52.06M	$51.13M	$51.13M
Other Receivables	$1.065M	$1.319M	$6.313M
Total Short-Term Assets	$386.5M	$507.8M	$507.8M
YoY Change	-33.44%	-19.12%	-19.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$86.72M	$83.46M	$95.62M
YoY Change	9.66%	2.59%	-3.34%
Goodwill	$22.06M	$22.06M
YoY Change	-84.59%	-84.58%
Intangibles	$141.0M	$143.1M
YoY Change	-5.18%	-5.04%
Long-Term Investments	$540.5M	$423.6M	$423.6M
YoY Change	47.34%	29.67%	29.67%
Other Assets	$32.68M	$34.90M	$43.19M
YoY Change	-27.91%	-20.9%	10.9%
Total Long-Term Assets	$843.4M	$727.5M	$727.5M
YoY Change	5.95%	-4.05%	-4.05%
TOTAL ASSETS
Total Short-Term Assets	$386.5M	$507.8M	$507.8M
Total Long-Term Assets	$843.4M	$727.5M	$727.5M
Total Assets	$1.230B	$1.235B	$1.235B
YoY Change	-10.67%	-10.87%	-10.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.62M	$15.36M	$15.36M
YoY Change	-11.16%	-33.49%	-33.49%
Accrued Expenses	$25.92M	$30.74M	$30.74M
YoY Change	22.9%	23.04%	23.04%
Deferred Revenue	$2.762M	$2.874M
YoY Change	1.06%	-10.16%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Long-Term Debt Due	$956.0K	$1.727M	$1.727M
YoY Change	0.21%	83.14%	83.14%
Total Short-Term Liabilities	$75.95M	$73.02M	$73.02M
YoY Change	-7.31%	-17.13%	-17.13%
LONG-TERM LIABILITIES
Long-Term Debt	$622.0K	$3.760M	$3.760M
YoY Change	-60.51%	106.82%	106.82%
Other Long-Term Liabilities	$13.91M	$15.08M	$11.32M
YoY Change	-13.48%	-17.28%	-31.02%
Total Long-Term Liabilities	$13.91M	$15.08M	$15.08M
YoY Change	-13.48%	-17.28%	-17.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$75.95M	$73.02M	$73.02M
Total Long-Term Liabilities	$13.91M	$15.08M	$15.08M
Total Liabilities	$103.2M	$102.0M	$99.23M
YoY Change	-4.27%	-12.17%	-16.87%
SHAREHOLDERS EQUITY
Retained Earnings	$619.7M	$633.2M
YoY Change	-21.12%	-20.95%
Common Stock	$511.3M	$501.7M
YoY Change	3.09%	3.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.130B	$1.136B	$1.136B
YoY Change
Total Liabilities & Shareholders Equity	$1.230B	$1.235B	$1.235B
YoY Change	-10.67%	-10.87%	-10.87%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$13.46M	-$128.1M	-$167.8M
YoY Change	-12.24%	437.72%	-217.03%
Depreciation, Depletion And Amortization	$6.663M	$6.533M	$26.14M
YoY Change	-3.14%	-33.35%	-19.96%
Cash From Operating Activities	$7.266M	$14.93M	$27.00M
YoY Change	-191.89%	-55.03%	-89.35%
INVESTING ACTIVITIES
Capital Expenditures	$4.056M	$3.106M	$22.21M
YoY Change	99.41%	-34.22%	18.28%
Acquisitions			$399.0K
YoY Change			-99.77%
Other Investing Activities	-$43.13M	$27.38M	$61.11M
YoY Change	1759.05%	-131.15%	-125.19%
Cash From Investing Activities	-$47.19M	$24.27M	$38.90M
YoY Change	983.74%	-126.21%	-114.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$25.06M
YoY Change			-66.29%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.807M	-25.95M	-47.79M
YoY Change	154.95%	-12.31%	-38.05%
NET CHANGE
Cash From Operating Activities	7.266M	14.93M	27.00M
Cash From Investing Activities	-47.19M	24.27M	38.90M
Cash From Financing Activities	-2.807M	-25.95M	-47.79M
Net Change In Cash	-42.80M	13.25M	17.97M
YoY Change	220.95%	-114.89%	-121.04%
FREE CASH FLOW
Cash From Operating Activities	$7.266M	$14.93M	$27.00M
Capital Expenditures	$4.056M	$3.106M	$22.21M
Free Cash Flow	$3.210M	$11.83M	$4.796M
YoY Change	-132.29%	-58.48%	-97.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001674930
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2023	us-gaap	Preferred Stock Redemption Date PreferredStockRedemptionDate	2027-07-31
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023	us-gaap	Operating Lease Income Comprehensive Income Extensible List OperatingLeaseIncomeComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#InterestAndOtherIncome
CY2022	us-gaap	Operating Lease Income Comprehensive Income Extensible List OperatingLeaseIncomeComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#InterestAndOtherIncome
CY2021	us-gaap	Operating Lease Income Comprehensive Income Extensible List OperatingLeaseIncomeComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#InterestAndOtherIncome
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37894
CY2023	dei	Entity Registrant Name EntityRegistrantName	FULGENT GENETICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-2621304
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4399 Santa Anita Avenue
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	El Monte
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91731
CY2023	dei	City Area Code CityAreaCode	626
CY2023	dei	Local Phone Number LocalPhoneNumber	350-0537
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	FLGT
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	628500000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29784771
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	DELOITTE & TOUCHE LLP
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97473000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79506000
CY2023Q4	flgt	Available For Sale Securities Debt Equity Securities And Trading Securities Current AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesCurrent	326681000
CY2022Q4	flgt	Available For Sale Securities Debt Equity Securities And Trading Securities Current AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesCurrent	446729000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	25226000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	41205000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	51132000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	52749000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	32559000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	48889000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	507845000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	627873000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	423571000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	326648000
CY2023Q4	flgt	Redeemable Preferred Stock Investment Noncurrent RedeemablePreferredStockInvestmentNoncurrent	20438000
CY2022Q4	flgt	Redeemable Preferred Stock Investment Noncurrent RedeemablePreferredStockInvestmentNoncurrent	12385000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83464000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	81353000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	143053000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	150643000
CY2023Q4	us-gaap	Goodwill Goodwill	22055000
CY2022Q4	us-gaap	Goodwill Goodwill	143027000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34902000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	44124000
CY2023Q4	us-gaap	Assets Assets	1235328000
CY2022Q4	us-gaap	Assets Assets	1386053000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15360000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	23093000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30737000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24981000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2874000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3199000
CY2023Q4	flgt	Customer Deposit CustomerDeposit	22700000
CY2022Q4	flgt	Customer Deposit CustomerDeposit	10895000
CY2022Q4	flgt	Investment Margin Liabilities Current InvestmentMarginLiabilitiesCurrent	14999000
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1183000
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	5639000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	164000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5301000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	73018000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	88107000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5978000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9836000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7962000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15084000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18235000
CY2023Q4	us-gaap	Liabilities Liabilities	102042000
CY2022Q4	us-gaap	Liabilities Liabilities	116178000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32416000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29653000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31248000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29438000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	501718000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	486585000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1205000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-20903000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	633175000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	801000000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1136101000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1266685000
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-2815000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	3190000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1133286000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1269875000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1235328000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1386053000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	289213000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	618968000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	992584000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	184757000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	252067000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	215533000
CY2023	us-gaap	Gross Profit GrossProfit	104456000
CY2022	us-gaap	Gross Profit GrossProfit	366901000
CY2021	us-gaap	Gross Profit GrossProfit	777051000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41440000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28910000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24219000
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	41467000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	38918000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	24439000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	88999000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	111074000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50732000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7845000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6497000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1708000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	120234000
CY2022	us-gaap	Restructuring Costs RestructuringCosts	2975000
CY2023	us-gaap	Operating Expenses OperatingExpenses	299985000
CY2022	us-gaap	Operating Expenses OperatingExpenses	188374000
CY2021	us-gaap	Operating Expenses OperatingExpenses	101098000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-195529000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	178527000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	675953000
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	21444000
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	5498000
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	1347000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-174085000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	184025000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	677300000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1154000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42102000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	174795000
CY2023	flgt	Income Loss Before Gain Loss On Equity Method Investments IncomeLossBeforeGainLossOnEquityMethodInvestments	-175239000
CY2022	flgt	Income Loss Before Gain Loss On Equity Method Investments IncomeLossBeforeGainLossOnEquityMethodInvestments	141923000
CY2021	flgt	Income Loss Before Gain Loss On Equity Method Investments IncomeLossBeforeGainLossOnEquityMethodInvestments	502505000
CY2021	flgt	Gain Loss On Equity Method Investments GainLossOnEquityMethodInvestments	3734000
CY2023	us-gaap	Profit Loss ProfitLoss	-175239000
CY2022	us-gaap	Profit Loss ProfitLoss	141923000
CY2021	us-gaap	Profit Loss ProfitLoss	506239000
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7414000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1480000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1125000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-167825000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	143403000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	507364000
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-5.63
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	4.76
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	17.25
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-5.63
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	4.63
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	16.38
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29784000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30097000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29408000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29784000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30964000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30976000
CY2023	us-gaap	Profit Loss ProfitLoss	-175239000
CY2022	us-gaap	Profit Loss ProfitLoss	141923000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1133286000
CY2023Q4	flgt	Common Stock Shares Not Issued And Holdback As Partial Security For Indemnification Obligations CommonStockSharesNotIssuedAndHoldbackAsPartialSecurityForIndemnificationObligations	185503
CY2022Q4	flgt	Common Stock Shares Not Issued And Holdback As Partial Security For Indemnification Obligations CommonStockSharesNotIssuedAndHoldbackAsPartialSecurityForIndemnificationObligations	371006
CY2023	us-gaap	Profit Loss ProfitLoss	-175239000
CY2022	us-gaap	Profit Loss ProfitLoss	141923000
CY2021	us-gaap	Profit Loss ProfitLoss	506239000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1200000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2665000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	456000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	24717000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-19940000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1548000
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-151722000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	119318000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	505147000
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7414000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1480000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1125000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	1409000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-2461000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	105000
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-6005000
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-3941000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1020000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-145717000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	123259000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	506167000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	569387000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15882000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	86000
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4155000
CY2021	us-gaap	Income Tax Effects Allocated Directly To Equity Cumulative Effect Of Change In Accounting Principle IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple	239000
CY2021	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	8151000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1092000
CY2021	us-gaap	Profit Loss ProfitLoss	506239000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1165880000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32640000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	31000
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1768000
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	74337000
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	28111000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-22605000
CY2022	us-gaap	Profit Loss ProfitLoss	141923000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1269875000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42922000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2732000
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	25060000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	23517000
CY2023	us-gaap	Profit Loss ProfitLoss	-175239000
CY2021	us-gaap	Profit Loss ProfitLoss	506239000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	120234000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	42922000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	32640000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	15882000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26143000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32662000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11004000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-880000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	32596000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	8931000
CY2023	flgt	Noncash Lease Expense NoncashLeaseExpense	6412000
CY2022	flgt	Noncash Lease Expense NoncashLeaseExpense	4913000
CY2021	flgt	Noncash Lease Expense NoncashLeaseExpense	1154000
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-305000
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-502000
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-850000
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	3911000
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-4767000
CY2021	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-7596000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	11466000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-8280000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-8188000
CY2023	flgt	Unrecognized Tax Benefits Operating Activities UnrecognizedTaxBenefitsOperatingActivities	3858000
CY2022	flgt	Unrecognized Tax Benefits Operating Activities UnrecognizedTaxBenefitsOperatingActivities	-9111000
CY2021	flgt	Unrecognized Tax Benefits Operating Activities UnrecognizedTaxBenefitsOperatingActivities	-348000
CY2023	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-589000
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-692000
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-1186000
CY2021	flgt	Gain Loss On Equity Method Investment GainLossOnEquityMethodInvestment	3734000
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	21000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	11000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	15000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2388000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-68638000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-42300000
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	572000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4337000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-7804000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6896000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-25339000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-12206000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	14208000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-31299000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	13081000
CY2022	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	-827000
CY2021	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	-52532000
CY2023	flgt	Increase Decrease In Operating And Finance Lease Liabilities IncreaseDecreaseInOperatingAndFinanceLeaseLiabilities	-6287000
CY2022	flgt	Increase Decrease In Operating And Finance Lease Liabilities IncreaseDecreaseInOperatingAndFinanceLeaseLiabilities	-4831000
CY2021	flgt	Increase Decrease In Operating And Finance Lease Liabilities IncreaseDecreaseInOperatingAndFinanceLeaseLiabilities	-1123000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	27003000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	253520000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	538577000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22207000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18775000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23812000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	32000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	775000
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	412000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	63000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	491914000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	417982000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	710490000
CY2022	flgt	Purchase Of Preferred Stock Of Privately Held Company PurchaseOfPreferredStockOfPrivatelyHeldCompany	15000000
CY2022	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	10000000
CY2021	flgt	Payment For Purchase Of Redeemable Preferred Stock PaymentForPurchaseOfRedeemablePreferredStock	20000000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	508558000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	232534000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	83842000
CY2023	flgt	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	44085000
CY2022	flgt	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	140176000
CY2021	flgt	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	185749000
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	399000
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	172679000
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	61868000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	38898000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-261314000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-546548000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	25060000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	74337000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2732000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1768000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4155000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	89475000
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	10000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	86000
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	730000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	700000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	7000
CY2023	flgt	Repayment Of Notes Payable RepaymentOfNotesPayable	4266000
CY2022	flgt	Repayment Of Notes Payable RepaymentOfNotesPayable	367000
CY2021	flgt	Repayment Of Notes Payable RepaymentOfNotesPayable	4000
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	15000000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-47785000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-77141000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	85405000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-149000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-453000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17967000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-85388000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	77468000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	79506000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	164894000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87426000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97473000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	79506000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	164894000
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	3261000
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	56193000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	237069000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	960000
CY2022	flgt	Stock Consideration In Business Combination StockConsiderationInBusinessCombination	28111000
CY2022	flgt	Maturities Of Marketable Securities In Other Current Assets MaturitiesOfMarketableSecuritiesInOtherCurrentAssets	19120000
CY2022	flgt	Noncash Or Part Noncash Purchase Of Fixed Assets In Notes Payable NoncashOrPartNoncashPurchaseOfFixedAssetsInNotesPayable	3833000
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	1799000
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	2989000
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	1075000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	573000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	1693000
CY2023	flgt	Operating Lease Right Of Use Assets Reduced Due To Lease Modification And Termination OperatingLeaseRightOfUseAssetsReducedDueToLeaseModificationAndTermination	142000
CY2022	flgt	Operating Lease Right Of Use Assets Reduced Due To Lease Modification And Termination OperatingLeaseRightOfUseAssetsReducedDueToLeaseModificationAndTermination	66000
CY2021	flgt	Operating Lease Right Of Use Assets Reduced Due To Lease Modification And Termination OperatingLeaseRightOfUseAssetsReducedDueToLeaseModificationAndTermination	399000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2661000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	52000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1797000
CY2023	flgt	Finance Lease Right Of Use Assets Reduced Due To Lease Modification Or Termination FinanceLeaseRightOfUseAssetsReducedDueToLeaseModificationOrTermination	696000
CY2021	flgt	Noncash Or Part Noncash Contingent Consideration For Business Acquisition Included In Current Liabilities NoncashOrPartNoncashContingentConsiderationForBusinessAcquisitionIncludedInCurrentLiabilities	10000000
CY2021	flgt	Noncash Or Part Noncash Public Offering Costs Included In Accounts Payable NoncashOrPartNoncashPublicOfferingCostsIncludedInAccountsPayable	5000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances. The Company’s estimates and assumptions may evolve as conditions change. Actual results could differ significantly from these estimates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) accounts receivable and allowances for credit losses, (iii) the useful lives of fixed assets and intangible assets, (iv) estimates of tax liabilities, (v) valuation of goodwill and indefinite-lived </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">intangible assets at time of acquisition and on a recurring basis, and (vi) valuation of investments.</span></p>
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	41205000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	11217000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1898000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-880000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	32596000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	8931000
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	15099000
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	2608000
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	499000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	25226000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	41205000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	11217000
CY2023Q4	flgt	Redeemable Preferred Stock Investment Noncurrent RedeemablePreferredStockInvestmentNoncurrent	20400000
CY2023	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	8100000
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-9600000
CY2023	flgt	Variable Consideration VariableConsideration	23000000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk, Customers and Suppliers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, trade accounts receivable, and marketable securities, which consist of debt securities and equity securities. As of December 31, 2023, substantially all of the Company’s cash and cash equivalents were deposited in accounts at financial institutions, and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash and cash equivalents are held.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. For the laboratory services segment, aggregating customers under common control, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total revenue in the years ended December 31, 2023, and a different customer comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">115.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">260.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of total revenue in the year ended December 31, 2022 and 2021, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">One</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer comprised </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total accounts receivable, net, as of December 31, 2023, and a different </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customer comprised </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of total accounts receivable, net, as of December 31, 2022. For the therapeutic development segment, the Company doesn't have customers or revenue as it does not have any commercialized or approved product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> therapeutic development business relies on ANP Technologies, Inc. for certain laboratory services, equipment, tools, and drug intermediates in connection with research and development efforts. The Company also relies on a limited number of suppliers for certain laboratory substances used in the chemical reactions incorporated into its processes, referred to as reagents, as well as for the sequencers and various other equipment and materials it uses in its laboratory operations. In particular, the Company relies on a sole supplier for the next generation sequencers and associated reagents it uses to perform its genetic tests and as the sole provider of maintenance and repair services for these sequencers. The Company’s laboratory operations would be interrupted if it encountered delays or difficulties securing these reagents, sequencers, other equipment or materials or maintenance and repair services, which could occur for a variety of reasons, including if the Company needs a replacement or temporary substitute for any of its limited or sole suppliers and is not able to locate and make arrangements with an acceptable replacement or temporary substitute. The Company's development efforts could also be delayed or interrupted if is unable to procure items needed for its therapeutic development activities. The Company believes there are currently only a few other manufacturers that are capable of supplying and servicing some of the equipment and other materials necessary for its laboratory operations, including collection kits, sequencers and various associated reagents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2023	flgt	Number Of Customer Types NumberOfCustomerTypes	3
CY2022	flgt	Tax Effects Related To Unrealized Holding Loss On Available For Sale Debt Securities TaxEffectsRelatedToUnrealizedHoldingLossOnAvailableForSaleDebtSecurities	7200000
CY2021	flgt	Tax Effects Related To Unrealized Holding Loss On Available For Sale Debt Securities TaxEffectsRelatedToUnrealizedHoldingLossOnAvailableForSaleDebtSecurities	437000
CY2023Q4	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	0
CY2023	flgt	Payable Balance Expected To Be Paid Off Date PayableBalanceExpectedToBePaidOffDate	2023-08
CY2023	flgt	Tax Effects Related To Unrealized Holding Loss On Available For Sale Debt Securities TaxEffectsRelatedToUnrealizedHoldingLossOnAvailableForSaleDebtSecurities	0
CY2023	flgt	Variable Consideration VariableConsideration	23000000
CY2023	flgt	Cumulative Catch Up Adjustment CumulativeCatchUpAdjustment	23000000
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2200000
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	14400000
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	26400000
CY2023	us-gaap	Revenue Practical Expedient Remaining Performance Obligation RevenuePracticalExpedientRemainingPerformanceObligation	true
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	38291000
CY2023Q4	flgt	Cash Equivalents CashEquivalents	38291000
CY2023Q4	flgt	Available For Sale Securities Debt Equity Securities And Trading Securities Amortized Cost Basis AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesAmortizedCostBasis	789726000
CY2023Q4	flgt	Available For Sale Securities Debt Equity Securities And Trading Securities Unrealized Gain Before Tax AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesUnrealizedGainBeforeTax	1909000
CY2023Q4	flgt	Available For Sale Securities Debt Equity Securities And Trading Securities Unrealized Loss Before Tax AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesUnrealizedLossBeforeTax	5945000
CY2023Q4	flgt	Available For Sale Securities Debt Equity Securities And Trading Securities AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecurities	785690000
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	32444000
CY2022Q4	flgt	Cash Equivalents CashEquivalents	32444000
CY2022Q4	flgt	Available For Sale Securities Debt Equity Securities And Trading Securities Amortized Cost Basis AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesAmortizedCostBasis	829515000
CY2022Q4	flgt	Available For Sale Securities Debt Equity Securities And Trading Securities Unrealized Gain Before Tax AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesUnrealizedGainBeforeTax	2000
CY2022Q4	flgt	Available For Sale Securities Debt Equity Securities And Trading Securities Unrealized Loss Before Tax AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesUnrealizedLossBeforeTax	28755000
CY2022Q4	flgt	Available For Sale Securities Debt Equity Securities And Trading Securities AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecurities	800762000
CY2023	flgt	Available For Sale Debt Securities And Equity Trading Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesAndEquityTradingSecuritiesGrossUnrealizedLoss	5900000
CY2022	flgt	Available For Sale Debt Securities And Equity Trading Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesAndEquityTradingSecuritiesGrossUnrealizedLoss	28800000
CY2023Q4	flgt	Fair Value Assets Transfers Between Levels Amount FairValueAssetsTransfersBetweenLevelsAmount	0
CY2022Q4	flgt	Fair Value Assets Transfers Between Levels Amount FairValueAssetsTransfersBetweenLevelsAmount	0
CY2021Q4	flgt	Fair Value Assets Transfers Between Levels Amount FairValueAssetsTransfersBetweenLevelsAmount	0
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	135097000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	124634000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51633000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	43281000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83464000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	81353000
CY2023	us-gaap	Depreciation Depreciation	17500000
CY2022	us-gaap	Depreciation Depreciation	25500000
CY2021	us-gaap	Depreciation Depreciation	9300000
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	12675000
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	15434000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7744000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6814000
CY2023Q4	flgt	Reagents And Supplies Current ReagentsAndSuppliesCurrent	5827000
CY2022Q4	flgt	Reagents And Supplies Current ReagentsAndSuppliesCurrent	4280000
CY2023Q4	flgt	Marketable Securities Interest Receivable Current MarketableSecuritiesInterestReceivableCurrent	4994000
CY2022Q4	flgt	Marketable Securities Interest Receivable Current MarketableSecuritiesInterestReceivableCurrent	2525000
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1319000
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	19836000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	32559000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	48889000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	19100000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7026000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1276000
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	6255000
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5558000
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	5741000
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	6667000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4215000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2134000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3957000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6132000
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	3543000
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	3214000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30737000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24981000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7147000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8795000
CY2023Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	4973000
CY2022Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	6068000
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2964000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	3372000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15084000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18235000
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	289213000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	618968000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	992584000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-195529000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	178527000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	675953000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26143000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32662000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11004000
CY2023Q4	us-gaap	Assets Assets	1235328000
CY2022Q4	us-gaap	Assets Assets	1386053000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	289213000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	618968000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	992584000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1368000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1138000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83464000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	81353000
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	51900000
CY2023Q4	us-gaap	Recorded Unconditional Purchase Obligation Due In Next Rolling Twelve Months RecordedUnconditionalPurchaseObligationDueInNextRollingTwelveMonths	29700000
CY2023Q4	us-gaap	Recorded Unconditional Purchase Obligation Due In Rolling Year Five RecordedUnconditionalPurchaseObligationDueInRollingYearFive	22200000
CY2023Q4	flgt	Estimated And Recorded Liability EstimatedAndRecordedLiability	6900000
CY2023	flgt	Operating Leases Term Of Expiration OperatingLeasesTermOfExpiration	2033-04
CY2023	flgt	Finance Leases Term Of Expiration FinanceLeasesTermOfExpiration	2026-12
CY2023Q4	flgt	Number Of Laboratories Certified Under Clinical Laboratory Improvement NumberOfLaboratoriesCertifiedUnderClinicalLaboratoryImprovement	2
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10838000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14784000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3957000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6132000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7147000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8795000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1316000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2784000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	544000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	943000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	760000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1818000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	470000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1782000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	366000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1693000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	550000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1550000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	12242000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	6875000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	5429000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1262000
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	758000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	683000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	7000
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	80000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	95000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1758000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1528000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	296000
CY2023	us-gaap	Lease Cost LeaseCost	9471000
CY2022	us-gaap	Lease Cost LeaseCost	7735000
CY2021	us-gaap	Lease Cost LeaseCost	1566000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M13D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0402
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M28D
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0374
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4309000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	532000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2358000
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	64000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11104000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1304000
CY2023	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	154000
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	269000
CY2021	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	413000
CY2023	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	10000
CY2022	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	12000
CY2021	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	7000
CY2023	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	164000
CY2022	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	281000
CY2021	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	420000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	90000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	90000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42922000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32640000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15882000
CY2023	flgt	Share Based Compensation Tax Benefit Expense From Vesting And Exercise Of Awards ShareBasedCompensationTaxBenefitExpenseFromVestingAndExerciseOfAwards	-2700000
CY2022	flgt	Share Based Compensation Tax Benefit Expense From Vesting And Exercise Of Awards ShareBasedCompensationTaxBenefitExpenseFromVestingAndExerciseOfAwards	2100000
CY2021	flgt	Share Based Compensation Tax Benefit Expense From Vesting And Exercise Of Awards ShareBasedCompensationTaxBenefitExpenseFromVestingAndExerciseOfAwards	13300000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-147464000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	189406000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	681403000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-26621000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5381000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4103000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-174085000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	184025000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	677300000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-5590000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	31140000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	131907000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-4722000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	19242000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	51076000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-10312000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	50382000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	182983000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-12771000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3763000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7471000
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4100000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-4517000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-717000
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-188000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	224000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	669000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.001
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0069
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2270
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2576
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-20325000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	224000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	669000
CY2023	flgt	Deferred Income Tax Expense Benefit Including Of Change In Valuation Allowance DeferredIncomeTaxExpenseBenefitIncludingOfChangeInValuationAllowance	11466000
CY2022	flgt	Deferred Income Tax Expense Benefit Including Of Change In Valuation Allowance DeferredIncomeTaxExpenseBenefitIncludingOfChangeInValuationAllowance	-8280000
CY2021	flgt	Deferred Income Tax Expense Benefit Including Of Change In Valuation Allowance DeferredIncomeTaxExpenseBenefitIncludingOfChangeInValuationAllowance	-8188000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1154000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42102000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	174795000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0022
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0903
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0613
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0018
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0092
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0005
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0165
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0112
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0196
CY2023	flgt	Effective Income Tax Rate Reconciliation Nondeductible Compensation EffectiveIncomeTaxRateReconciliationNondeductibleCompensation	-0.0055
CY2022	flgt	Effective Income Tax Rate Reconciliation Nondeductible Compensation EffectiveIncomeTaxRateReconciliationNondeductibleCompensation	0
CY2021	flgt	Effective Income Tax Rate Reconciliation Nondeductible Compensation EffectiveIncomeTaxRateReconciliationNondeductibleCompensation	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.1062
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0
CY2023	flgt	Effective Income Tax Rate Reconciliation Federal Return To Provision EffectiveIncomeTaxRateReconciliationFederalReturnToProvision	-0.0021
CY2022	flgt	Effective Income Tax Rate Reconciliation Federal Return To Provision EffectiveIncomeTaxRateReconciliationFederalReturnToProvision	-0.0392
CY2021	flgt	Effective Income Tax Rate Reconciliation Federal Return To Provision EffectiveIncomeTaxRateReconciliationFederalReturnToProvision	-0.0017
CY2023	flgt	Effective Income Tax Rate Reconciliation State Return To Provision EffectiveIncomeTaxRateReconciliationStateReturnToProvision	0.0341
CY2022	flgt	Effective Income Tax Rate Reconciliation State Return To Provision EffectiveIncomeTaxRateReconciliationStateReturnToProvision	-0.0202
CY2021	flgt	Effective Income Tax Rate Reconciliation State Return To Provision EffectiveIncomeTaxRateReconciliationStateReturnToProvision	-0.0014
CY2023	flgt	Effective Income Tax Rate Reconciliation Other Permanent Differences EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences	-0.0115
CY2022	flgt	Effective Income Tax Rate Reconciliation Other Permanent Differences EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences	0.0133
CY2021	flgt	Effective Income Tax Rate Reconciliation Other Permanent Differences EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences	0.0109
CY2023	flgt	Effective Income Tax Rate Reconciliation Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment	0.0319
CY2022	flgt	Effective Income Tax Rate Reconciliation Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment	-0.0298
CY2021	flgt	Effective Income Tax Rate Reconciliation Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment	-0.0033
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0242
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0011
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0034
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0019
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.122
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	807000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1488000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	818000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	10255000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17496000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16345000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	906000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2550000
CY2023Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	211000
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	4892000
CY2023Q4	flgt	Deferred Tax Assets Excess Tax Basis In Net Assets DeferredTaxAssetsExcessTaxBasisInNetAssets	2256000
CY2022Q4	flgt	Deferred Tax Assets Excess Tax Basis In Net Assets DeferredTaxAssetsExcessTaxBasisInNetAssets	2032000
CY2023Q4	flgt	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	2345000
CY2022Q4	flgt	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	4086000
CY2023Q4	flgt	Deferred Tax Assets Unrealized Gain Loss On Available For Sale Debt Securities DeferredTaxAssetsUnrealizedGainLossOnAvailableForSaleDebtSecurities	406000
CY2022Q4	flgt	Deferred Tax Assets Unrealized Gain Loss On Available For Sale Debt Securities DeferredTaxAssetsUnrealizedGainLossOnAvailableForSaleDebtSecurities	7664000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1258000
CY2023Q4	flgt	Deferred Tax Assets Research And Experimental Expenditures DeferredTaxAssetsResearchAndExperimentalExpenditures	18606000
CY2022Q4	flgt	Deferred Tax Assets Research And Experimental Expenditures DeferredTaxAssetsResearchAndExperimentalExpenditures	6573000
CY2023Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	503000
CY2022Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	503000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	107000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	199000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	45719000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	56587000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15900000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2832000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	29819000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	53755000
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	30558000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	39199000
CY2023Q4	flgt	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	3901000
CY2022Q4	flgt	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	5500000
CY2023Q4	flgt	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2299000
CY2022Q4	flgt	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	4056000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1023000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1496000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	37781000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	50251000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7962000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	3504000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15900000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2800000
CY2022Q4	flgt	Unrecognized Tax Benefits Excluding Interest Liability UnrecognizedTaxBenefitsExcludingInterestLiability	9742000
CY2021Q4	flgt	Unrecognized Tax Benefits Excluding Interest Liability UnrecognizedTaxBenefitsExcludingInterestLiability	710000
CY2020Q4	flgt	Unrecognized Tax Benefits Excluding Interest Liability UnrecognizedTaxBenefitsExcludingInterestLiability	377000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	3845000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2843000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	64000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6189000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	333000
CY2023Q4	flgt	Unrecognized Tax Benefits Excluding Interest Liability UnrecognizedTaxBenefitsExcludingInterestLiability	5833000
CY2022Q4	flgt	Unrecognized Tax Benefits Excluding Interest Liability UnrecognizedTaxBenefitsExcludingInterestLiability	9742000
CY2021Q4	flgt	Unrecognized Tax Benefits Excluding Interest Liability UnrecognizedTaxBenefitsExcludingInterestLiability	710000
CY2023Q4	flgt	Unrecognized Tax Benefits Excluding Interest Liability UnrecognizedTaxBenefitsExcludingInterestLiability	5800000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2300000
CY2023Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	145000
CY2022Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	94000
CY2023	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	145000
CY2022	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	94000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-167825000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	143403000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	507364000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29784000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30097000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29408000
CY2022	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	55000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29784000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30964000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30976000
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-5.63
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	4.76
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	17.25
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-5.63
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	4.63
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	16.38
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	74300000
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1800000
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	3200000
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2500000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	697000
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	24022000
CY2021	flgt	Business Acquisitions Pro Forma Operating Income Loss BusinessAcquisitionsProFormaOperatingIncomeLoss	-2756000
CY2022Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	250000000
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	953000
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	25100000
CY2023Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	150700000
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	143053000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	150643000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7800000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6500000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	7976000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	7976000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7671000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	7210000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	7175000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	40455000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	78463000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-24-022233-index-headers.html	Edgar Link	pending
0000950170-24-022233-index.html	Edgar Link	pending
0000950170-24-022233.txt	Edgar Link	pending
0000950170-24-022233-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
flgt-20231231.htm	Edgar Link	pending
flgt-20231231.xsd	Edgar Link	pending
flgt-ex10_41.htm	Edgar Link	pending
flgt-ex21_1.htm	Edgar Link	pending
flgt-ex23_1.htm	Edgar Link	pending
flgt-ex31_1.htm	Edgar Link	pending
flgt-ex31_2.htm	Edgar Link	pending
flgt-ex32_1.htm	Edgar Link	pending
flgt-ex4_2.htm	Edgar Link	pending
img232190488_0.jpg	Edgar Link	pending
img232190488_1.jpg	Edgar Link	pending
img232190488_2.jpg	Edgar Link	pending
img232190488_3.jpg	Edgar Link	pending
img232190488_4.jpg	Edgar Link	pending
img232190488_5.jpg	Edgar Link	pending
img232190488_6.jpg	Edgar Link	pending
img232190488_7.jpg	Edgar Link	pending
img232190488_8.jpg	Edgar Link	pending
flgt-20231231_htm.xml	Edgar Link	completed
img232190488_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FLGT
Fulgent Genetics, Inc. Stock $flgt

2024 Q1 Form 10-K Financial Statement

#000095017024022233 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FLGT Fulgent Genetics, Inc. Stock $flgt

2024 Q1 Form 10-K Financial Statement

#000095017024022233 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FLGT
Fulgent Genetics, Inc. Stock $flgt